Intangible Assets and Royalty Agreement (Details) (USD $)	3 Months Ended	12 Months Ended							0 Months Ended		12 Months Ended		0 Months Ended	3 Months Ended	12 Months Ended			12 Months Ended				12 Months Ended				12 Months Ended						12 Months Ended					12 Months Ended					12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013 Licenses		Dec. 31, 2012 Licenses		Jan. 29, 2007 Licenses Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.	Dec. 31, 2013 Licenses Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.	Dec. 31, 2013 Licenses SaluMedica, LLC	Dec. 31, 2012 Licenses SaluMedica, LLC	Mar. 31, 2008 Licenses HydroFix	Dec. 31, 2013 Licenses HydroFix	Dec. 31, 2012 Licenses HydroFix	Jan. 05, 2011 Licenses Surgical Biologics, LLC		Dec. 31, 2013 Patents & Know How		Dec. 31, 2012 Patents & Know How		Dec. 31, 2013 Patents & Know How Surgical Biologics, LLC		Jan. 05, 2011 Patents & Know How Surgical Biologics, LLC		Dec. 31, 2013 Customer & Supplier Relationships		Dec. 31, 2012 Customer & Supplier Relationships		Jan. 05, 2011 Customer & Supplier Relationships Surgical Biologics, LLC		Dec. 31, 2013 Tradenames & Trademarks		Dec. 31, 2012 Tradenames & Trademarks		Jan. 05, 2011 Tradenames & Trademarks Surgical Biologics, LLC	Dec. 31, 2013 In Process Research & Development		Dec. 31, 2012 In Process Research & Development		Jan. 05, 2011 In Process Research & Development Surgical Biologics, LLC	Dec. 31, 2013 Patents in Process		Dec. 31, 2012 Patents in Process
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives					10 years	[1],[2],[3],[4]												14 years	[1]							14 years	[1]
Gross Carrying Value					$ 6,075,000	[1],[2],[3],[4]	$ 6,075,000	[1],[2],[3],[4]								$ 13,000	[1],[2],[3],[4]	$ 7,798,910	[1]	$ 7,690,000	[1]			$ 7,690,000	[1]	$ 3,761,000	[1]	$ 3,761,000	[1]	$ 3,761,000	[1]
Weighted Average Amortization Lives, Indefinite Lived																																indefinite	[1]				indefinite	[1]				indefinite	[5]
Gross Carrying Value, Indefinite Lived																																1,008,000	[1]	1,008,000	[1]	1,008,000	25,000	[1]	25,000	[1]	25,000	579,987	[5]	0	[5]
Intangible Assets, Gross Carrying Value	19,247,897	19,247,897	18,559,000
Less Accumulated amortization and impairment charges	(8,069,324)	(8,069,324)	(6,647,251)
Intangible Assets, Net	11,178,573	11,178,573	11,911,749
Acquisition price									996,000		2,399,000		2,667,000
Maximum time of approval									30 days
Contingent payments to licensor										200,000
Contingent royalty to be paid to licensor (in hundredths)										3.00%
Annual royalty payment									50,000
Net book value	10,170,573	10,170,573								309,000
Impairment charge	368,000		1,800,000									851,676		368,102	946,819
Finite-Lived Intangible Assets, Costs																						108,910	[1]
Amortization of intangible assets		1,053,971	1,380,241	1,335,908
Estimated future amortization expense [Abstract]
2014	923,935	923,935
2015	923,935	923,935
2016	923,935	923,935
2017	834,302	834,302
2018	824,335	824,335
Thereafter	5,740,131	5,740,131
Net book value	$ 10,170,573	$ 10,170,573								$ 309,000

[1] On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2013 an additional $108,910 of costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.

[2] On September 1, 2005, we acquired a license from SaluMedica, LLC (SaluMedica) in the original amount of $2,399,000 for the use of certain developed technologies related to spine repair. This license was acquired through the acquisition of SpineMedica Corp. In 2012, we booked an impairment charge related to this asset of $851,676. In the fourth quarter of 2013, the Company made a decision to discontinue marketing the HydroFix® product line and fully impaired the asset. There was no charge to Operations as the asset was fully amortized.

[3] On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol cryogel in the original amount of $2,667,000. In 2012, we booked an impairment charge related to this asset of $946,819. In the fourth quarter of 2013, the Company made a decision to discontinue marketing the HydroFix® product line and fully impaired the asset. This resulted in an impairment charge of $368,102 which is included in the Company's Statement of Operations.

[4] On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2013, this license had a remaining net book value of approximately $309,000.

[5] Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.